S-1: Scilex S-1: Tumim Equity Line & Product Pipeline Update

Scilex Holding Company files an S-1 registration statement for the resale of up to 1.39 million common shares by Tumim Stone Capital, securing a potential $100 million equity financing to bolster its non-opioid pain management portfolio and operations.

Summary

• Scilex Holding Company filed an S-1 registration statement for the resale of up to 1,390,443 shares of common stock by Tumim Stone Capital, LLC.
• The resale shares include 150,000 Commitment Shares and up to 1,240,443 shares the company may elect to sell to Tumim under a Common Stock Purchase Agreement.
• The Tumim Purchase Agreement provides for a potential $100,000,000 in aggregate gross proceeds from sales of common stock to Tumim, at the company's discretion.
• Proceeds from the Tumim Equity Financing are intended for working capital and general corporate purposes, including R&D, regulatory affairs, clinical trials, acquisitions, and debt management.
• Scilex's commercial products include ZTlido (lidocaine topical system) 1.8%, ELYXYB (oral solution for migraine), and GLOPERBA (liquid oral colchicine for gout), with GLOPERBA launched in June 2024.
• The company's pipeline features SP-102 (SEMDEXA) for sciatica (Phase 3 completed), SP-103 (triple-strength lidocaine topical system) for acute pain (Phase 2 completed), and SP-104 (low-dose naltrexone) for fibromyalgia (Phase 1 completed).
• Net revenue for the three months ended March 31, 2025, was $5.0 million, a decrease from $10.9 million in the same period of 2024, primarily due to a $6.3 million decrease in ZTlido sales.
• Net loss for the three months ended March 31, 2025, was $26.1 million, compared to $24.4 million for the same period in 2024.
• As of March 31, 2025, cash and cash equivalents were approximately $5.8 million, and the accumulated deficit was $589.1 million.
• The company's negative working capital was $247.0 million as of March 31, 2025.
• The Oramed Note's maturity date was extended from March 21, 2025, to December 31, 2025, in exchange for 92,857 shares of common stock.
• The company entered into new royalty purchase agreements for GLOPERBA and ELYXYB (4% of net sales) and amended the ZTlido royalty agreement.
• A 1-for-35 reverse stock split was effected on April 15, 2025, reducing outstanding shares from approximately 243.3 million to 6.95 million.
• Scilex formed a joint venture, Scilex Bio, Inc., on April 17, 2025, contributing 5.0 million shares of Semnur Common Stock for a 60% ownership interest.
• The Semnur Business Combination, involving a merger with Denali Capital Acquisition Corp., is expected to close in Q3 2025.
• The company has an option to repurchase 6.5 million Penny Warrants from Oramed for $27 million, with payments due by September 30, 2025 ($13 million) and December 31, 2025 ($14 million).
• Certain Tranche B Warrants were exchanged for New Warrants at an exercise price of $40.00 per share, expiring October 8, 2029.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including recurring losses, negative working capital, and substantial doubt about its ability to continue as a going concern. While it has secured a potential equity line and has promising product candidates, the immediate financial performance and regulatory hurdles for its pipeline products present considerable headwinds. The revenue decline in Q1 2025 is a notable negative.

Positives

• Secured a potential $100 million equity financing commitment from Tumim Stone Capital, providing a flexible funding source for operations and growth.
• Successfully launched two new commercial products, ELYXYB (April 2023) and GLOPERBA (June 2024), diversifying revenue streams beyond ZTlido.
• GLOPERBA received FDA approval as the first and only liquid oral version of colchicine for gout prophylaxis, and ELYXYB received Health Canada approval for migraine treatment.
• SP-102 (SEMDEXA) has completed a pivotal Phase 3 study with positive primary and secondary endpoint results, positioning it for potential FDA approval as the first ESI for sciatica.
• SP-103 received FDA Fast Track status for acute low back pain and showed promising safety and efficacy in Phase 2 trials, with plans to prioritize development for acute pain.
• The company's management team has extensive experience in biopharmaceutical development and commercialization, with a strong track record.
• ZTlido has achieved significant market acceptance, covering over 200 million lives in the U.S. through managed healthcare formularies.
• Resolved the OTC Action litigation with Sanofi and Hisamitsu, and the GLOPERBA Patent Litigation with Takeda, reducing legal uncertainties and costs.
• Regained compliance with Nasdaq's minimum bid price requirement following the reverse stock split.

Negatives

• Experienced a significant decrease in net revenue for the three months ended March 31, 2025, primarily due to a 55% decrease in ZTlido gross sales volume.
• Incurred continued net losses of $26.1 million for Q1 2025 and $72.8 million for the year ended December 31, 2024, with an accumulated deficit of $589.1 million.
• Has negative working capital of $247.0 million as of March 31, 2025, raising substantial doubt about its ability to continue as a going concern.
• Heavily dependent on ZTlido sales, with ELYXYB and GLOPERBA still in initial commercialization stages, posing revenue concentration risk.
• The Oramed Note and Tranche B Notes impose restrictive operating and financial covenants, and any non-compliance could lead to default and adverse financial impact.
• Will require substantial additional funding, which may not be available on acceptable terms or at all, potentially leading to reduced operations or delayed development.
• The company is currently ineligible to file new short form registration statements on Form S-3 due to past failure to timely file a quarterly report, impairing capital raising flexibility.
• The FDA indicated that the clinical data for SEMDEXA from the single Phase 3 CLEAR-1 trial was not sufficient for 505(b)(2) NDA submission, requiring an additional confirmatory trial.
• The reverse stock split may reduce and limit market trading liquidity and could lead to a decrease in overall market capitalization if the per-share price does not increase proportionally.
• The company relies on sole or single-source suppliers for key products and raw materials, posing supply chain disruption risks.

Risks

• Ability to maintain Nasdaq listing and public securities liquidity and trading.
• Ability to raise future financing on acceptable terms.
• Expected use of proceeds from future equity or convertible debt issuances.
• Future financial performance, including revenue, costs of revenue, and operating expenses.
• Ability to use cash on hand to meet current and future financial obligations, including funding operations, debt service, and capital expenditures.
• Outcome of any legal proceedings that may be instituted against the company.
• Ability to attract and retain qualified directors, officers, employees, and key personnel.
• Ability to compete effectively in a highly competitive market, especially against larger biotechnology companies.
• Ability to protect and enhance corporate reputation and brand.
• Impact from future regulatory, judicial, and legislative changes in the industry.
• Ability to obtain and maintain regulatory approval of any products and product candidates.
• Ability to research, discover, and develop additional product candidates.
• Ability to grow and manage growth profitably.
• Ability to obtain and maintain intellectual property protection and not infringe on the rights of others.
• Ability to execute business plans and strategy.
• Ability to prevent, respond to, and recover from a cybersecurity incident.
• Effect of geopolitical conflicts or new/increased international tariffs on business operations, clinical studies, and trials.
• Effect of global economic and political developments, including conflicts in Ukraine and Israel.
• Dependence on commercial success of ZTlido, ELYXYB, and GLOPERBA, with the latter two in initial commercialization stages.
• Terms of the Oramed Note and Tranche B Notes imposing operating and financial covenants, with potential for default.
• Requirement for substantial additional funding, which may not be available on acceptable terms.
• Inability to generate sufficient cash to service indebtedness and other liquidity needs.
• Recurring losses from operations, negative cash flows, and substantial cumulative net losses raising substantial doubt about going concern.
• Material weaknesses in internal control over financial reporting, potentially leading to inaccurate financial reporting.
• Reliance on sole or single-source suppliers and manufacturers for commercial and clinical supply, and raw materials.
• Reliance on third parties to conduct clinical trials, with risks of non-compliance or delays.
• Interim top-line and preliminary data from clinical trials may change as more data becomes available.
• ZTlido, GLOPERBA, and ELYXYB may have undesirable properties, and product candidates may cause undesirable side effects.
• Disruption in research and development facilities.
• Failure to realize anticipated benefits of acquisitions, which can be costly and dilutive.
• Exposure to business, legal, regulatory, political, operational, financial, and economic risks associated with international business.
• Risks and challenges from increasing use of social media platforms.
• Unstable market and economic conditions adversely affecting business.
• Challenges in effectively monitoring and responding to corporate responsibility, governance, and sustainability expectations.
• Product liability lawsuits leading to substantial liabilities or commercialization limitations.
• Inability to maintain patent protection or if scope is not sufficiently broad.
• Inability to obtain or maintain necessary rights to product components, processes, and brands through acquisitions and in-licenses.
• Claims challenging inventorship or ownership of patents and intellectual property.
• Claims of infringement, misappropriation, or violation of third-party intellectual property rights.
• Failure to obtain patent term extension and data exclusivity.
• Inability to protect confidentiality of trade secrets.
• Employees, independent contractors, consultants, commercial partners, and vendors engaging in misconduct or improper activities.
• Non-compliance with health and data protection laws and regulations.
• Impact of new U.S. administration actions, including executive orders, policies, new legislation, and judicial decisions.
• Use of hazardous materials and compliance with environmental laws and regulations.
• Dilution to existing stockholders from sale and issuance of common stock to selling stockholder.
• Fluctuation of market price of common stock due to various factors, including investor expectations and analyst reports.
• Future sales, or perception of future sales, of substantial number of shares causing price decline.
• Operating results fluctuating significantly.
• Cash and cash equivalents adversely affected if financial institutions fail.
• Ability to use net operating loss and tax credit carryforwards may be limited.
• Estimates or judgments relating to critical accounting policies proving incorrect.
• Anti-takeover provisions in governing documents and Delaware law making acquisition more difficult.
• Warrants may never be in the money or expire worthless, and terms may be amended adversely.
• Redemption of unexpired SPAC Warrants prior to exercise.
• Increased costs from operating as a public company and management time devoted to compliance initiatives.
• Comprehensive U.S. federal income tax reform adversely affecting the company.
• Ineligibility to file new short form registration statements on Form S-3.

Future Outlook

Scilex anticipates continued significant expenses for commercialization of its products and R&D of its product candidates, expecting to incur substantial losses for the foreseeable future. The company plans to finance operations through equity offerings, debt financings, collaborations, government contracts, or other strategic transactions. Future success depends on successful commercialization and regulatory approvals, with specific plans to prioritize SP-103 development for acute pain and continue efforts for SEMDEXA and SP-104. The company aims to expand its product portfolio by developing or acquiring non-opioid assets that leverage its novel delivery and adhesion technologies and existing commercial infrastructure.

Management Comments

• Our guiding principle has always been and remains a patient-first approach, which drives our mission to meet the increasing global demand for more effective and safer non-opioid pain management solutions.
• Through rigorous research and development, we believe we are on the cusp of establishing Scilex as the preeminent name in commercial non-opioid pain management, specifically targeting the unmet needs in both acute and chronic pain sectors with our innovative and leading therapies.
• We believe that we have not only responded to the global demand for safer, more effective pain relief solutions, but also made substantial progress in demonstrating the rapid onset and enhanced safety of our products.
• Our management has concluded that there is substantial doubt about our ability to continue as a going concern for one year after the date that the consolidated financial statements are issued.

Industry Context

The filing highlights Scilex's position in the non-opioid pain management market, a sector driven by increasing global demand for safer alternatives to opioids. The company's strategy of acquiring, developing, and commercializing non-opioid products aligns with broader industry trends focusing on addressing high unmet needs in acute and chronic pain. Competition is intense, with larger pharmaceutical and biotechnology companies having greater resources. Scilex aims to differentiate through novel delivery technologies (ZTlido, SP-103) and unique formulations (ELYXYB, GLOPERBA, SEMDEXA, SP-104) that address specific limitations of existing treatments, such as poor adhesion in topical patches or risks associated with off-label injections. The regulatory environment, including FDA's scrutiny on off-label uses and evolving data diversity requirements, significantly impacts product development and commercialization strategies. The increasing focus on cost containment by third-party payors also pressures pricing and reimbursement, a common challenge across the pharmaceutical industry.

Comparison to Industry Standards

• ZTlido demonstrated significantly improved adhesion compared to Lidoderm (a branded, prescription 5% lidocaine patch product) and Mylan's generic lidocaine patch in head-to-head studies, maintaining over 90% mean adhesion over 12 hours, a key FDA benchmark.
• ZTlido achieved a bioequivalent dose of lidocaine with a reduced drug load (36 mg vs. 700 mg for Lidoderm), leading to less residual drug and lower accidental exposure risk.
• ZTlido's label allows use under moderate exercise and showering/bathing conditions, unlike Lidoderm and associated generics, which are labeled to avoid water exposure.
• ZTlido's label allows use after moderate heat exposure, unlike Lidoderm and associated generics.
• SP-102 (SEMDEXA) aims to be the first FDA-approved epidural steroid injection for sciatica, addressing risks associated with currently used off-label particulate steroids (e.g., methylprednisolone acetate, triamcinolone acetonide, betamethasone sodium phosphate/acetate) that carry warnings of serious neurologic complications.
• SP-103 is designed to deliver three times the lidocaine dose of approved topical products, including ZTlido, potentially offering a higher-strength option for acute pain.
• SP-104 (low-dose naltrexone) aims to overcome inaccuracies and side effects (hyperalgesia, dysphoria, nausea, anxiety, insomnia) associated with pharmacy-compounded or high-dose commercial naltrexone products for fibromyalgia by using a delayed-release formulation and night-time administration.

Management Changes

Corporate Governance

Legal Proceedings

• **Former Employee Action**: Scilex Pharma and Sorrento filed a lawsuit on March 12, 2021, against former President Anthony Mack and Virpax Pharmaceuticals, Inc., alleging breach of restrictive covenant, tortious interference, breach of fiduciary duties, and misappropriation of trade secrets. The court found in favor of the Plaintiffs on most counts on September 1, 2023. A definitive settlement agreement with Virpax was reached on February 29, 2024, involving cash payments of $3.5 million (received) and $2.5 million (received July 8, 2024), plus future royalties on certain drug candidates (Epoladerm, Probudur, Envelta). Litigation against Mr. Mack remains ongoing, with the parties awaiting a final judgment on remedies after oral argument on November 15, 2024.
• **ZTlido Patent Litigation**: On June 22, 2022, Scilex filed a complaint against Aveva Drug Delivery Systems, Inc. and Apotex Corp. alleging infringement of ZTlido patents following Apotex's ANDA submission. The lawsuit sought to prevent generic ZTlido marketing until patent expiration (latest May 10, 2031). The U.S. District Court for the Southern District of Florida issued a decision on August 26, 2024, finding Aveva's product does not infringe. Scilex is appealing this decision to the U.S. Court of Appeals for the Federal Circuit, with briefing underway.
• **GLOPERBA Patent Litigation**: On November 6, 2023, Takeda Pharmaceuticals U.S.A., Inc. filed a complaint against Scilex alleging infringement of Colcrys patents due to Scilex's proposed GLOPERBA label revision. A settlement agreement and non-exclusive license agreement with Takeda were entered into on March 7, 2024, resolving the action. A final consent judgment was entered on May 3, 2024, after no objections from the FTC and DOJ.

Related Party Transactions

• **Stockholder Agreement with Sorrento**: Terminated on September 21, 2023, following the Equity Repurchase Transaction. Previously, Sorrento had significant rights, including designating directors and requiring consent for certain corporate actions.
• **Intercompany Dividend**: On July 4, 2023, Scilex Pharma distributed $20,000,000 to Legacy Scilex, which then distributed it to Scilex.
• **Junior Debtor-in-Possession Financing with Sorrento**: In July 2023, Scilex provided Sorrento with a $20.0 million junior secured term loan facility (Junior DIP Facility). This facility was terminated on September 21, 2023, and the transfer of funds was accounted for as a capital distribution to Sorrento.
• **Stock Purchase Agreement with Sorrento**: On September 21, 2023, Scilex repurchased 1,716,245 shares of Common Stock, 29,057,097 shares of Series A Preferred Stock, and certain warrants from Sorrento. Consideration included assuming Sorrento's $100 million Senior DIP Facility obligations, a credit bid for the Junior DIP Facility, a $10.0 million cash payment, and assuming $12.25 million in Sorrento's legal fees. Sorrento no longer holds a majority voting interest.
• **Oramed Note**: Issued to Oramed Pharmaceuticals Inc. on September 21, 2023, for $101.9 million, partially in exchange for a reduction in Sorrento's outstanding obligations to Oramed. Oramed is a significant holder of Scilex's debt and warrants.
• **Tranche B Notes**: Issued on October 8, 2024, to institutional investors and Oramed for $50.0 million. Oramed's portion ($22.5 million) was an exchange and reduction of its principal balance under the Oramed Note.
• **ZTlido Royalty Purchase Agreement**: Entered on October 8, 2024, with ZTlido Royalty Investors and Oramed, selling the right to receive 8% of ZTlido/SP-103 net sales worldwide. Oramed's portion of the purchase price ($2.5 million) was paid by exchanging a portion of the Oramed Note.
• **Gloperba-Elyxyb Royalty Purchase Agreement**: Entered on February 28, 2025, with institutional investors and Oramed, selling the right to receive 4% of Gloperba/Elyxyb net sales worldwide (excluding Canada).
• **Oramed Penny Warrant Repurchase Option**: On July 22, 2025, Scilex entered an Option Agreement with Oramed to repurchase 6.5 million Penny Warrants for $27 million. This agreement also extends the Oramed Note maturity date to March 31, 2026, if the repurchase is completed.
• **Warrant Exchange Agreements**: On July 22, 2025, Scilex exchanged certain Tranche B warrants with holders (including 3i, LP, an affiliate of Tumim) for new warrants.
• **Tumim Equity Financing**: On July 22, 2025, Scilex entered a Common Stock Purchase Agreement with Tumim Stone Capital, LLC, allowing Scilex to sell up to $100 million of common stock to Tumim. Tumim is a related party through its affiliate 3i, LP, a Tranche B Noteholder.
• **Scilex Bio JV**: On April 17, 2025, Scilex formed a joint venture with IPMC Company, contributing 5.0 million shares of Semnur Common Stock for a 60% ownership interest. IPMC Company contributed certain assets for a 40% interest.
• **Convertible Promissory Note from Denali**: Denali Capital Acquisition Corp. issued a convertible promissory note to Scilex, with potential conversion into Denali shares upon business combination.
• **Sponsor Interest Purchase Agreement (SIPA)**: On August 30, 2024, Scilex agreed to purchase 500,000 Class B ordinary shares of Denali from Denali Capital Global Investments LLC (the Sponsor), a related party through the Semnur Business Combination, for $2.0 million cash and 8,571 shares of Common Stock.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future equity issuances, including the Tumim Equity Financing and warrant exercises. The reverse stock split may impact trading liquidity and market capitalization. The ongoing net losses and going concern doubt pose substantial investment risk. The Series 1 Preferred Stock dividend, if paid, could provide a pro rata portion of Semnur Common Stock, but its payment and mandatory exchange are contingent.
• **Employees**: The company's financial instability and going concern doubt could impact job security and future compensation. Stock-based compensation plans are in place to attract and retain talent, but their value is tied to stock performance. Management changes and the ongoing 'great resignation' could affect employee morale and retention.
• **Customers**: Continued commercialization efforts for ZTlido, ELYXYB, and GLOPERBA aim to provide effective non-opioid pain management solutions. However, potential supply chain disruptions from single-source suppliers could affect product availability. Pricing and reimbursement policies by third-party payors directly impact patient access and affordability.
• **Suppliers/Creditors**: The company's reliance on sole/single-source suppliers creates dependency. Creditors, particularly holders of the Oramed Note and Tranche B Notes, face risks related to the company's ability to service its debt, with various covenants and potential default scenarios. The extension of debt maturity dates and royalty agreements indicate ongoing financial management efforts.
• **Regulatory Bodies**: The company's compliance with FDA and other regulatory requirements is critical for product approvals and commercialization. Ongoing legal proceedings and the need for additional clinical trials (e.g., for SEMDEXA) highlight regulatory scrutiny and potential delays.

Next Steps

• Analyze SP-103 Phase 2 trial data and ZTlido investigator study data for chronic neck pain.
• Prioritize further potential development of SP-103 for the treatment of acute pain.
• Initiate a planned multi-center placebo-controlled registration trial for SP-104 for fibromyalgia.
• Conduct an additional confirmatory trial for SP-102 (SEMDEXA) as requested by the FDA prior to a 505(b)(2) NDA filing.
• Continue to explore and evaluate additional opportunities to grow the business through acquisitions or in-licensing.
• Continue to make investments in sales and marketing organization and expand digital marketing efforts for ZTlido, GLOPERBA, and ELYXYB.
• Continue to negotiate coverage with large payors and pharmacy benefit managers for ZTlido, ELYXYB, and GLOPERBA.
• Support investigator-initiated research studies for ZTlido in carpal tunnel syndrome, neck pain, intercostal neuralgia, and other indications.
• Identify and certify new suppliers for sodium hyaluronate for SP-102.
• Appeal the U.S. District Court's decision regarding ZTlido Patent Litigation to the U.S. Court of Appeals for the Federal Circuit.
• Await final judgment from the court regarding remedies against Mr. Mack in the Former Employee Action.
• Potentially repurchase Penny Warrants from Oramed in two tranches by September 30, 2025, and December 31, 2025.
• Tumim Stone Capital may begin purchasing shares under the Tumim Purchase Agreement once the S-1 registration statement is effective.
• The Semnur Business Combination is expected to close during the third quarter of 2025.

Key Dates

Recommendation

Scilex Holding Company presents a high-risk, high-reward profile. The company has a promising pipeline of non-opioid pain management products and has secured a significant equity financing commitment, which provides some liquidity. However, the substantial net losses, negative working capital, and explicit 'going concern' doubt raise serious financial viability concerns. The recent revenue decline for its flagship product, ZTlido, is a negative indicator. While the potential for FDA approval of SEMDEXA and the commercialization of ELYXYB and GLOPERBA offer upside, these are subject to significant regulatory and market uncertainties. The stock has experienced extreme volatility, and the reverse stock split may further impact liquidity. For a seasoned investor, the current situation warrants a 'hold' as the company navigates its financial challenges and attempts to advance its pipeline. A 'buy' would be premature given the significant financial risks and operational hurdles, while a 'sell' might forgo potential upside if the company successfully executes its strategy and addresses its liquidity issues.

Keywords

Scilex Holding Company, S-1 filing, equity financing, Tumim Stone Capital, non-opioid pain management, ZTlido, ELYXYB, GLOPERBA, SEMDEXA, SP-103, SP-104, biopharmaceutical, clinical trials, FDA approval, intellectual property, debt financing, Nasdaq Capital Market, reverse stock split, corporate governance, risk factors, pharmaceutical industry, neuropathic pain, migraine, gout, sciatica, fibromyalgia